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The current state of  quantification 
of  myocardial perfusion with PET: 
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Nuclear cardiology has shown a full-blown development during the last 
three decades. From the implementation of myocardial perfusion, function 
and viability studies, the tools to address cardiovascular pathological states 
in a non-invasive manner have steadily extended the methods and techniques 
of  the currently available state-of-the art panel (1–3). This particular area of 
medical sciences emerges from a very clear need to approach cardiac disease 
in a novel, integrative, effective and patient-friendly way within the setting 
of the increased mortality and chronic burden that it has shown since the 20th 
century.
The path of innovation has followed substantial leaps from the initial 
advent of radio-isotopic ventriculography, to the implementation of single-
photon emission tomography (SPECT) during the 70s and thereon to the 
introduction of positron emission tomography (PET) in the early 80s. More 
recently, the concept of hybrid imaging with computed tomography (CT) 
or magnetic resonance (MR) has made its way with the offer to optimize 
our diagnostic and prognostic comprehension of the heart and its (patho)
physiological processes; this refers to the modern SPECT/CT, PET/CT and 
PET/MR systems which convey complementary physiologic and anatomic 
information. However, intrinsic added values within PET imaging, such as 
the measurement of ventricular function, are also worth of notice.
Why has this accelerated development taken place? And why 
addressing the cardiovascular disease burden when there are several 
alternative areas in which scientific and technological developments are also 
required? The answer can be found in statistics and its striking estimates. 
Today, cardiovascular disease constitutes one of the leading causes of death 
in the “western” world (4). Thus, in spite of our tremendous advances in 
cardiovascular treatment, our epidemiological profile has been marginally 
modified.
It is true, however, that the profile of the “cardiac” patient regarding 
modifiable risk factors and treatments has evolved; in consequence, lifestyle 
and longevity have been changing staggeringly. Then, cardiovascular 
medicine in the XXI century has been confronted with the more “chronic” 
front of coronary artery disease. This front ranges from patients with 
an intermediate cardiovascular risk (according to the traditional risk 
stratification methods, rather outdated in my point of view) for which 
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we still lack optimal algorithms, to the post-infarcted and revascularized 
patients. Furthermore, there is another substantial proportion of them who 
suffer from progressive heart dysfunction with an elevated mortality and, 
most importantly, a decreased quality of life. 
This may somehow appear oxymoronic, since one may argue that it is 
precisely a subjectively appealing lifestyle (for some) which accelerates and 
worsens coronary artery disease and resulting ischemia, but that is matter 
for a different discussion.
It is here where nuclear cardiology has found its niche by offering a 
better and deeper insight into cardiac (patho)physiology, an offer with an 
embedded promise of diagnostic and prognostic optimization, of better-
selected advanced therapy (personalized and precision medicine) and of a 
consequent downstream effect into improving the cardiac disease profile, a 
promise that is steadily being fulfilled.
Positron-emission tomography myocardial perfusion imaging (PET-
MPI) has loomed and crystalized within nuclear medicine techniques during 
the last three decades due to its ability to assess myocardial blood flow 
(MBF) in absolute terms. Currently, PET-MPI represents the gold standard 
modality for this purpose (5). By fueling the enthusiasm of cardiovascular 
scientists and physicians, this approach in cardiac imaging has propelled 
the non-invasive assessment of cardiac physiology and pathophysiology to 
a new state-of-the-art.
Translational research for MBF quantification has been an intense 
research topic and even though its complete integration into daily practice 
has not been accomplished, the intrinsic diagnostic and prognostic added 
value of the modality has been robustly demonstrated. Moreover, cardiac 
PET is able to evaluate aspects of cardiac function at no further expense. 
The present review aims to summarize the evidence behind the increasingly 
suggested clinical importance of cardiac PET quantitative perfusion and 
cardiac function in the setting of diagnosis and prognosis of coronary 
artery disease (CAD). Additionally, the technique’s principles, methods and 
particularities, and future perspectives will be presented.
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PET PRINCIPLES IN MYOCARDIAL 
PERFUSION SCANNING
PET technology uses coincidence detection of pairs of high-energy 
hotons that are emitted (γ-rays with an angle of 180˚ between them and 
energy of 511 KeV) from the “annihilation” of an emitted positron with a 
free electron as shown in Figure 1. These positrons arise from the decay of 
radiopharmaceuticals administered to the patient in order to track (patho)
physiological processes. 
The two photons are detected in opposite sides of the ring detectors 
embedded in the camera. Improved detectors (LSO, LYSO or LGSO) that are 
coupled to optimized electronics yield high peak count rates and currently, 
events can be detected in a 3D mode through the entire cardiac field-of-view. 
The hybrid composition of the scanners allows for the use of CT to create an 













Presently, “list-mode” acquisition is performed in order to reconstruct 
static, dynamic and gated images with a single radiotracer injection. In such 
a modality all of the acquisition measured coincidences and the time tags are 
saved in a file for retrospective processing.
Static data is traditionally reconstructed from the final frame (≈900ms) 
obtained for visual and semi-quantitative interpretation (% uptake relative 
to a reference region, usually the one with the highest uptake). Further, 
myocardial perfusion absolute quantification is derived from the sequential 
dynamic first-pass images which, when paired to the EKG or respiratory 
gating, further permit evaluation of LV contractile function (both during 
systole and diastole) and phase synchrony. 3D-mode acquisitions convey 
higher sensitivity and optimized corrections. In turn, this facilitates reduction 
in injected doses and therefore optimization of dosimetry (see Dosimetry).
Methods for optimizing image reconstruction have been implemented 
including filtered-back projection and currently, the widely used iterative 
reconstruction approaches. Iterative reconstructions deliver images with 
reduced noise and enhanced myocardium contrast and resolution, with 
added improved temporal resolution (7). Due to sensitivity to counts and 
the nature of the detection, PET scanning has proven superior image quality 
and therefore increased diagnostic accuracy over SPECT (8).
PET Imaging Protocols
PET myocardial perfusion imaging (MPI) is conducted in a two or 
three phase acquisition, namely: during rest and pharmacologically-induced 
stress or during rest, cold-pressor test (CPT) and pharmacologically-induced 
stress. The total acquisition time will therefore depend on the number of 
performed phases, the stress-induction protocol, the length of the dynamic 
imaging (which depends upon the tracer) and the CT imaging (in hybrid 
equipment) (7). In average a full rest-stress and CT acquisition can be 
performed in 30 to 40 minutes (9), a shorter time when compared to SPECT 
due to the half-life of the radiotracers. 
Quantitative perfusion begins with a topogram acquisition for patient 
positioning. Then a CT transmission scan is acquired. Afterwards, the 
radiotracer is injected (25–50 mCi of 82Rb, 10–30 mCi of 15O-H2O or 20 mCi 





















































































































































































































































































































































































































and 400 MBq depending on the center of 13N-ammonia) and the rest imaging 
acquisition is initiated simultaneously (5-6 minutes for 82Rb or 15O-H2O 
and 10 minutes for 13N-ammonia) (10–12). After completion, a second CT 
transmission scan is performed for the stress phase. Then, stress is induced 
and a second dose of radiotracer is injected and the stress imaging acquisition 
is performed. The most common pharmacologic stressors are adenosine and 
regadenoson, and they are administered as a 6-minute infusion of 140µg/
kg/min two or three minutes before the injection of the radiotracer or a 0.4 
mg bolus injected over 15-20 seconds and followed by a 10mL saline flush 
before the injection of the radiotracer, respectively. With 15O-H2O and 82Rb, 
the second phase can be performed without delay after the first study. 
However, with 13N-ammonia the second study (stress or rest) is routinely 
delayed 30 min after the first study to allow for radiotracer decay and the 
image acquisition is started a few seconds before the radiotracer injection. 
In other centers, a routine correction for subtracting residual activity may 
also be applied. In hybrid equipment, the acquisition is completed with a CT 
angiography and a coronary artery calcium scan. Figure 2 depicts example 
protocols for PET and PET/CT.
Clinical protocols have not yet been established for new promising 
tracers such as 18F-fluripiridaz, but the tracer’s half-life (see Perfusion 
Radiotracers) poses theoretical challenges and advantages to consider in the 
near future. Currently, pilot studies are being conducted.
Dosimetry
Several current standards for PET-MPI, such as 3D acquisition and 
state-of-the-art software offer the possibility for reduced radiation doses. A 
full 82Rb 3D PET scan implies an exposure of 4.3 mSv, while for a single 
13N-ammonia 3D scan, the estimated the radiation dose is 1 mSv, and 0.8 
mSv for 15O-H2O (10,13). The calculated exposure for 18F-fluripiridaz has 
initially been estimated in 6.3 mSv (14). 
The present modality of hybrid PET/CT imaging poses an additional 
exposure due to the CT acquisition within the same protocol. Nevertheless, 
with recent improvements in CT technology and the optimization of all-
inclusive protocols, a full PET/CT imaging can be performed with a radiation 
dose under 10 mSv (15).




Several radiotracers have proved suitable for performing adequate 
and reproducible PET-MPI. The most commonly used are summarized in 
Table 1.
13N-ammonia. This radiotracer represents an attractive compound 
with a relatively short half-life (9.96 min) and appealing uptake kinetics. 
13N-ammonia undergoes a cell-trapping process due to its conversion to 
glutamine inside the cell (10,11). The favorable positron range (2.53 mm) and 
an 80% extraction fraction allow acquisition of intermediate- to high-quality 
images. The production of 13N-ammonia requires an on-site cyclotron, 
limiting its availability. Nevertheless, smaller single-site cyclotrons presently 
offer unit dose production of 13N-ammonia (12). Research on results from 
this production are not yet available.
15O-H2O. 15O-H2O portraits the ideal radiotracer for flow quantification 
due to its free diffusion through the cell membrane and proportional 
tissue uptake to flow. 15O-H2O has a physical half-life of 2.06 min and an 
intermediate positron range (4.14 mm). Remarkably, its extraction fraction 
is 100%. Derived image quality has been considered suboptimal (for visual 
analysis) due to a jeopardized contrast between intra- and extravascular 
compartments. Nevertheless, clinical research has recently demonstrated the 
feasibility (16) and diagnostic quality of parametric imaging with 15O-H2O 
(17). This radiotracer also requires an on-site cyclotron for its production and 
unlike 13N-ammonia, its half-life does not allow for distribution to nearby 
imaging centers.
13N-ammonia 15O-H2O 82Rubidium 18F-fluripiridaz
Half-life 9.96 min 2.06 min 76 sec 109 min
Positron range (mm) 2.53 4.14 8.6 1.03
Myocardial Extraction (%) 80 100 65 94
Perfusion-defect contrast Intermediate Intermediate Lowest Highest
Cyclotron needed Onsite or nearby Onsite No In the region
Table 1. PET perfusion radiotracer characteristics.
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82Rubidium. 82Rb was one of the first introduced PET tracers. Notably, 
it does not require an on-site cyclotron for its production. Instead, 82Rb can 
be obtained from commercially available elution generators which have a 
5-week shelf life, but availability has been hindered by limits in 82Strontium 
production. Presently, it constitutes the most used PET perfusion radiotracer 
in the USA. 82Rb is potassium analog with a short physical half-life (76 s) 
with kinetic properties comparable to 201Thallium. It has a lower extraction 
fraction than other tracers as well as a longer positron range (8.6 mm) which 
limits the resolution of the generated images (12). Nevertheless, due to its 
versatility, the greatest body of evidence and experience has been generated 
around 82Rb perfusion studies.
Nowadays, research efforts have been dedicated to the development of 
new 18Fluorine based perfusion radiotracers in order to attend to the growing 
need for providing access to PET perfusion radiotracers for a greater number 
of patients. 18Fluorine based tracers offer a relatively long half-life of 110min. 
As such, compounds like 18F-fluripiridaz, fluorodihydrorotenone (18F-FDHR)
(12) and several iterations of triphenyl phosphonium salts are currently 
under development.
18F-Fluripiridaz is a tracer that inhibits NADH:ubiquinone 
oxidoreductase by competing for binding with ubiquinone without affecting 
the cardiac cell viability. It has demonstrated a short positron range (1.03 
mm) and a high extraction fraction (94%) (18) offering improved image 
quality as documented by phase I (19) and II trials (14). Quantification over a 
wide range of MBF with 18F-Fluripiridaz has been performed with engaging 
results (20).
18Fluorine-labeled phosphonium derivates (18F-FATPs) have 
demonstrated potential for PET-MPI in preclinical studies. 18F-FATPs 
accumulate in cardiac myocytes due to their higher mitochondrial membrane 
potential (21) and show intense myocardial uptake with sharp delineation of 
perfusion defects in animal models (22). 18F-FATPs have been compared to 
13N-ammonia and favorable findings warrant further extension into clinical 
studies in the coming years (23).
Dedicated Software
Several tailored software are available for automatic image 
reconstruction and blood flow quantification with minimum observer 
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intervention such as QPS (24), syngoMBF, 4DM, PMOD, EcTB, CARIMAS(25), 
FlowQuant (26) amongst others. 
Due to heterogeneity in the models and reconstruction software 
application recent research has been conducted to investigate whether 
estimations of flow with one or another model, software or scanner are 
to be considered interchangeable. There is evidence of good agreement 
between software packages for blood flow quantification with 82Rb (27) and 
13N-ammonia (28) studies and it has been stated that reconstruction using 
a wide range of software, under the assumption of a 1-tissue-compartment 
mode, has sufficient agreement to be used interchangeably. Nevertheless, 
it has also been demonstrated that agreement is not optimal between 
estimations derived from different kinetic models (29). In summary, the 
choice of a kinetic model seems to constitute a greater influence in the 
feasibility of MBF comparison than the software used. Provided that the 
kinetic model applied will also depend on the used radiotracer, there is an 
evident added level of complexity in the matter.
Since current software alternatives allow quick and mostly automated 
estimations of parameters such as MBF, current challenges for software 
development and utilization mostly rely on the impending need for 
standardization, models and estimates validation. 
Quantification of Myocardial Perfusion
Dynamic acquisitions are used to map the distribution and concentration 
of the radiotracer during rest and stress throughout the myocardium by 
applying tracer kinetic models, which account for the influence of partial 
volume effect, spatial resolution, and motion. Usually, a one or two-tissue 
compartment model is considered (according to the tracer) and first-pass 
activity distribution (K1 = extraction) and derived global and regional time-
activity curves yield estimation of the absolute myocardial blood flow. 
Features that increase the value of such estimations are the high temporal 
resolution of the technique as well as the compulsory correction of photon 
attenuation.
MBF is then generally corrected for the rate-pressure product (RPP) 
an index of myocardial oxygen consumption. Since the relation between 
RPP and MBF is decoupled during stress, the correction is only made for 
Chapter 1
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rest MBF (30–32). Additional corrections such as residual activity correction 
can be made according to the protocol followed and radiotracer used. 
MBF is measured in milliliters per gram of tissue per minute (ml/g/min); 
theoretically, this allows for comparable magnitudes across studies and 
pathologic conditions (see Dedicated Software and Chapter 7 of this Thesis).
Stress MBF and the ratio between stress and rest flow are used to 
evaluate the vasodilatory capacity of the coronary artery tree globally for the 
left ventricle as well as regionally based on several proposed segmentations 
such as the 17-segment model proposed by the American Heart Association 
or the vessel territory segmentation (see Figure 3) (33).
Comparison of MBF during the two or three scan phases evaluates 
the endothelium-dependent and independent (vascular muscle dependent) 
coronary responses. The ratio of CPT-MBF to rest MBF is known as the 
endothelial-dependent vasodilatory index (EDVI), while the ratio of stress 
MBF to rest MBF is known as the coronary flow reserve or myocardial 
perfusion reserve (MPR). Pharmacological or exercise stress evokes a 








LAD. left anterior descending
LCx.  left circumflex


















Figure 3. AHA - LV segmentation models. Modified from the American College of Cardiology 
Foundation. 2009;53(1):76-90.
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coronary vascular function expressed by MPR.
Several factors exert a direct influence in the coronary vasodilator 
capacity and there is no simple relationship between pathologic-morphologic 
features (from non-invasive or invasive angiography) and perfusion 
defects. Notably, stress MBF and MPR have been recognized as important 
physiological parameters of cardiovascular health. These measurements 
have shown an inverse relationship with increasing severity of epicardial 
obstructive CAD and stress-induced regional perfusion defects (34). 
Nevertheless, a marked variability is present across individual patients.
Since quantitative PET merges the perfusion dynamics of the main 
epicardial vessels and the microvascular circulatory detail in an integrative 
measurement, abnormal results in this evaluation should be carefully 
considered in accordance to factors that may hamper microvascular 
circulation additionally to flow-limiting subepicardial vessel stenoses. 
Hybrid imaging (PET/CT and PET/MR) has arisen in response to this need 
given the clinical importance of making this distinction. 
Therefore, quantitative perfusion assessment may result useful to 
identify vasomotor abnormalities preceding overt CAD, improve diagnostic 
accuracy for CAD, estimate the burden of the disease in the full extent of the 
coronary system, potentially evaluate the effect of medical interventions and 
enhance risk assessment for optimal prognostic evaluation.
Ventricular Function Evaluation with PET
The simultaneous evaluation of ventricular function constitutes a rather 
underestimated and underutilized capability of PET-MPI. Reconstruction of 
PET data acquired in “list-mode” can be binned into a determinate number of 
frames (usually 8 or 16) for the average cardiac cycle. By automatic contouring 
of the endocardial and epicardial surfaces, end-systolic and end-diastolic 
volumes can be calculated and ventricular contraction and relaxation based 
on wall motion and thickening can be tracked and quantified (35) (Figure 4).
Systolic Function 
This is achieved by gating or synchronizing the acquisition to the 
surface EKG for accurate characterization of ventricular motion through the 























Figure 4. EKG-gating and time-volume curve generation. The average volumes per frame are 
used to trace the ejection and filling of the left ventricle.
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fraction (LVEF), the main surrogate for systolic function, can be accurately 
reported at rest and peak-stress (as opposed to the post-stress offered by 
SPECT) (37). 
Diastolic Function and Synchrony
Although, less commonly and so far mainly for research purposes, 
diastolic function and ventricular synchrony are also evaluated with PET. 
These aspects of ventricular function are understood as an extension in 
PET imaging that follow other validated techniques for such evaluation, 
such as SPECT, echo or radioisotope ventriculography. Thinking back 
into the intrinsic advantages of PET over more traditional techniques, 
one may hypothesize that PET-derived estimates are, therefore, accurate 
and reproducible. However, validated “normal” measurement ranges 
and clinically meaningful cutoffs are scarcely studied and warrant further 
research. 
Estimates of diastolic function are numerous and they vary from 
technique to technique. For instance, there are several measurements offered 
by echocardiography, a quick and easy modality. However, concerns on 
reproducibility and variation are present. 
Regarding PET, several measurements may be derived from the 
behavior of the ventricular filling curves (see Figure 5), which differ between 
control and diseased patients. 
Figure 5. Example curves showing contrasting curves from a patient with normal ventricular 
filling (left) and a patient with a hampered filling (right) as shown by a higher and a lower 
filling rate in the beginning of the diastolic time.  EDV/s, end-diastolic volumes per second; 
MFR/3, mean filling rate during the first third of diastole; RR, R-R interval
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Analysis of synchrony can be performed through phase evaluation, 
possible with several software packages. This data is derived through the 
first-harmonic fast Fourier transformation from the gated PET datasets. 
Uniformity of the onset and progression of wall motion throughout the 
cardiac cycle in the left ventricle (38) is expressed by measurements derived 
form a histogram where bandwidth, its standard deviation (39) and entropy 
can be obtained (40) as seen in Figure 6. Previous studies on synchrony have 
been conducted for SPECT and a small but increasing number of publications 
on PET have used synchrony for risk stratification and selection of patients 
in need for bi-ventricular pacing (41–43).
The limiting step for proving clinical utility of ventricular functional 
measures has been found on the complexity and cost of the technique. 
Certainly, one would not require performing a PET-CT scan for the isolated 
evaluation of LVEF. Instead, these added values of PET must be understood 
as complements of perfusion and anatomic findings for gauging severity 
and functional impact in the ventricular dynamics. 
Figure 6. Synchrony analysis. Example phase analysis of contrasting patients with (right) and 
without (left) a previous myocardial infarction, measurements of synchrony are given from 
the histograms obtained. St Dev, standard deviation




Microvascular Disease and Treatment Monitoring
Through the years, several reports using PET have demonstrated 
microvascular dysfunction in narrowly selected subsets of patients with 
specific cardiovascular risk factors such as smoking (45), dyslipidemia 
(46,47), hypertension (48), insulin resistance, diabetes mellitus (49) and 
rheumatic diseases (50).
The EDVI and the MPR have been evaluated to detect impairment 
of coronary endothelial function and total vasodilatory function (51), 
respectively. Results from these studies suggest that non-invasive evaluation 
through quantitative PET can demonstrate impaired vasomotor function 
in the presence of cardiovascular risk factors (52). This may serve as a 
pathophysiological proxy of subclinical CAD, which might benefit from 
intense life-style modification.
Noteworthy, some studies have shown improvement in MBF 
dynamics through several interventions (53) and after long-term risk factor 
modification (54). This evidence suggests that treatment follow-up is feasible 
through quantitative PET. Nevertheless, doubts regarding the feasibility 
of this approach due to radiation exposure and costs should be further 
addressed. Notably, special patient populations may benefit from such an 
approach considering their morbidity profile (autoimmune disorders as 
vasculitis) and are to be contemplated in a patient-to-patient basis. 
Characterizing the burden of coronary artery disease
PET has long been known to be an excellent study to detect regional 
myocardial perfusion defects, being accepted as the reference standard for 
this determination in a non-invasive manner and yielding a sensitivity of 
81% and a specificity of 89% for angiographically significant coronary artery 
stenoses (55). Moreover, the clinical significance of the coronary lesions 
may also be appropriately assessed non-invasively through PET, potentially 
sparing the patient from subsequent unnecessary invasive procedures such 
as coronary angiography. Figure 7 depicts a patient with intermediate risk 
of CAD investigated for myocardial ischemia. In this regard, PET displays 
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a sensitivity of 84% and a specificity of 87% for the detection of functionally 
significant lesions evaluated by fractional flow reserve (FFR) (a gauge of the 
functional relevance of atherosclerotic plaques) (56).
Flow quantification represents an additional feature that places PET 
above other non-invasive techniques in some aspects. One of the well-known 
applications is the scenario where perfusion is altered throughout several 
myocardial regions. In this setting, traditional semiquantitative assessment of 
PET imaging fails to comprehensively characterize perfusion abnormalities 
due to its relative nature.
On the other hand, global and regional reduction of perfusion can be 
demonstrated through quantitative measurements, which are independent 
























Figure 7. PET MPI. PET MPI study of a 53 year-old patient undergoing evaluation for 
suspected CAD. The study shows moderate ischemia in the inferolateral wall (gray arrows), 
suggestive of left circumflex coronary artery and/or right coronary artery lesion. PET, Positron 
Emission Tomography; MPI, Myocardial Perfusion Imaging; CAD, Coronary Artery Disease.
The current state of  quantification of  myocardial perfusion with PET
29
1
becomes a matter of additive diagnostic information. The distinction 
between diffuse microvascular disease and multiple subepicardial vessel 
affection may prove difficult due to the fact that both conditions provoke 
a hampered perfusion. For example, multimodality imaging has linked 
perfusion abnormalities to coronary ectasia with and without atherosclerotic 
lesions (57,58). A lack of distinction can lead to falsely negative results and 
underestimation of the cardiac risk in certain groups of patients. Another 
particular scenario is posed by patients with trivascular involvement who 
present such a “pseudonormalization” phenomenon or “balanced” ischemia 
can be adequately studied with flow quantification (57) (e.g. in Figure 8), 
although this phenomenon may be less prevalent than originally considered. 
More commonly, quantitative perfusion aids in the characterization 
of patients with single-, two- or three-vessel disease with a differential in 
perfusion impairment between coronary vessels. While, techniques like 
SPECT or even semiquantitative analysis with PET may report findings 
compatible with one-vessel CAD, quantification contributes with objective 
measures for the rest of the vessel territories providing a comprehensive 
view on the impact of CAD over the coronary circulation (e.g. in Figure 9). 
Still, while a preserved MPR has shown a very high negative predictive value 
for excluding high-risk CAD, abnormalities in MPR alone cannot distinguish 
the level of the coronary tree affected by the suspected CAD(59). 
Regional reductions in perfusion may thus be due to flow-limiting 
effects of coronary lesions or, as mentioned earlier, microvascular dysfunction 
related to cardiovascular risk factors, and the discrimination of effects cannot 
be addressed by the measurement alone even though several cutoff values 
have been studied in order to optimize their interpretation. These studies 
have addressed invasive angiography and invasive FFR as the diagnostic 
standard (60,61).
Diagnostic performance improvement for CAD has been studied with 
similar results showing improvement in sensitivity and specificity by adding 
the quantitative evaluation, which in turn, does not require much more effort 
in the acquisition protocol making it an attractive technical addition (Figure 
2) (62). Studies for establishing the most adequate threshold for abnormal 
stress MBF and MPR have been conducted and current evidence suggests 
that the former might yield a better diagnostic and prognostic value in the 
setting of CAD (60,63).
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Figure 8. MBF Quantification in multivessel CAD. PET MPI study showing very mild 
ischemic findings in the anteroapical and apicolateral segments in the semi-quantitative 
analysis. Nevertheless, quantitative assessment shows a reduced stress MBF and MPR in 
all arterial territories, achieving a better characterization of the trivascular disease, owing to 
a balanced ischemia or pseudonormalization phenomenon. MBF, Myocardial Blood Flow; 
CAD, Coronary Artery Disease; PET, Positron Emission Tomography; MPI, Myocardial 
Perfusion Imaging; CFR, Coronary Flow Reserve.
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It is evident then, that MBF quantification and derived measures 
are to be considered within the integral PET MPI study as added values, 
which aid and improve the quality of the conclusions drawn from it. It has 
been stated that abnormal quantitative measurements are to be interpreted 
in addition to parallel anatomic and functional assessments in order to 
complement the information obtained and pinpoint the best way to proceed 
into the therapeutic process. It is here where hybrid modalities arise offering 
the added value of complementary anatomical and functional information. 
Whether its utilization will lead to improved patient outcomes is still to 
be answered. The essence of quantification as a “gatekeeper” for cardiac 
catheterization should strive for, in turn, moderating revascularization 
procedures. 
In this way, the added value of flow quantification has expanded the 
possibilities of the technique from basic detection of advanced flow-limiting 
epicardial CAD to the broad evaluation of subclinical disease, the better 
characterization of its burden and the unmasking of multivessel perfusion 
affection. 
In the setting of functional evaluation LVEF has been noted to increase 
during vasodilator stress in normal subjects, but in CAD patients, LVEF 
changes relate inversely with the magnitude of reversible perfusion defects 
and of angiographic findings (64). On these basis, LVEF can be incorporated 
into clinical PET evaluation. More recently, SPECT ventricular synchrony 
has been related to an increasing burden of invasively assessed CAD (65) 
although data in PET imaging is still scarce. 
RISK EVALUATION AND PROGNOSTIC 
PERFORMANCE
Quantitative Perfusion
Recent and ongoing research is trying to address one on the most 
important questions around cardiac PET/CT application: whether its 
prognostic yield is relevant in comparison with more accessible techniques. 
In this regard, there is a discrete but growing amount of studies aiming to 
clarify this issue (66). With the possibility of measuring the MBF in absolute 
terms, recent publications have shown the correlation and incremental 
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prognostic utility and added value of MPR measurements in the mid and 
long-term follow-up (67), including after revascularization procedures (68). 
It has been shown that when applying the most common indications for PET 
MPI, which include chest pain, dyspnea or both, roughly half of the studies 
were classified as normal according to the semi-quantitative visual analysis. 
Short-term follow up studies have evaluated MPR as a relevant marker for 
prediction of cardiovascular events even within the subgroup of patients 
without regional perfusion abnormalities and previously infracted patients. 
This supports the notion that MPR can be considered as an integrative marker 
for CV risk independently of previous CV events. Interestingly enough, 
stress MBF assessment no longer resulted predictive of CV outcomes in 
patients with no regional perfusion abnormalities (69). Conversely, recent 
research has demonstrated a better performance of stress MBF for prediction 
of cardiac events.
At the same time, the non-invasive measurement of MPR has been able 
to identify patients at increased risk of cardiac mortality in that a preserved 
MPR (≥2.0) conveys an extremely low rate of cardiac mortality in contrast to 
Figure 9. Quantitative PET/CT (hybrid) in suspected CAD. PET MPI study showing severe 
semiquantitative ischemia in the inferior ventricular wall, suggestive of RCA involvement. 
Nevertheless, quantitative assessment shows a reduced stress MBF (0.90 ml/g/min) and 
MPR (2.23) in the same territory in comparison to the rest of the ventricular walls. CCTA 
documented non-calcified plaques with proximal RCA ectasia (7 mm).
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patients with severely reduced MPR (hazard ratio of 5.6), even suggesting 
a “3-year warranty” event-free period. Moreover, MPR has shown utility 
in patient risk reclassification within the intermediate cardiovascular risk 
population (up to one third), which may constitute a mayor advantage for 
the technique considering that quantitative evaluation of MBF through PET 
MPI does not bear additional costs, procedures or radiation exposure (70). 
Additionally, PET MPI also results advantageous in the stress study of high 
risk subsets of patients such as those with heart failure and obesity (71).
In the absence of epicardial stenosis, a decreased MPR is considered 
to document microvascular dysfunction caused by traditional CV risk 
factors, reflecting an early stage within the CAD horizon, while a preserved 
MPR portrays an excellent mid-term prognosis in patients with otherwise 
common risk factors. Moreover, quantitative PET MPI abnormalities have 
demonstrated to predict heart failure outcomes (72), and MPR has been 
evaluated as a stronger predictor for cardiac death than left ventricle ejection 
fraction (73).
Ventricular Function
 Data on the prognostic value of PET-measured LVEF has proposed 
that it constitutes a powerful risk marker for cardiac mortality, along with 
ventricular volumes. In patients with low resting LVEF, stress myocardial 
perfusion is able to further stratify risk of adverse events. On the other 
hand, a lower value of stress LVEF in patients with comparable perfusion 
abnormalities conveys a higher risk. Finally, a negative LVEF reserve (% of 
increase from rest to peak-stress) suggests a higher risk of annualized cardiac 
events when compared to positive reserves (44,74).
Recent findings from prognostic studies may be valuable in determining 
which patients could be adequately managed medically and which would 
need further testing or interventional procedures to improve mortality rates. 
Furthermore, recent studies are unequivocally shifting towards the inclusion 
of enriched and geographically diverse groups of patients in an attempt to 
enhance the generalizable implications of its results. A systematic approach 
to review the available evidence of the prognostic value of quantification of 




Nowadays, most of the available centers for PET scanning utilize it in 
the form of hybrid equipment, mostly in combination with CT scan (PET/
CT), and in a much more discreet, but growing degree, with MRI (PET/MRI). 
This is important because PET/CT provides complementary information 
(75). On one side, it documents the evaluation of intrinsic physiological and 
functional processes through PET (depending on the selected radiotracer and 
quantitative analysis) and on the other side, it delivers an accurate anatomical 
evaluation of the heart, the coronary vessels and related structures. This 
allows us to frame a comprehensive image of the disease, compensating for 
each technique’s individual drawbacks at the same time (76). 
The addition of computed tomography coronary angiography (CTCA) 
and coronary calcium scoring helps to clarify the etiology of the perfusion 
defects, which could be attributed to flow-limiting lesions, unexpected 
artifacts, or false positive results (inherent to every technique). This is due 
to the ability of contrast enhanced CTCA to directly characterize coronary 
stenosis and plaque gross structure. CTCA has established itself as a useful 
method in the clinical scenario for resolving unclear PET MPI results, defining 
multivessel disease in “at glance” normal perfusion studies and excluding 
significant CAD in low and intermediate cardiovascular risk patients (77,78).
There seems to be an improvement in sensitivity, specificity and 
accuracy with hybrid PET/CT (95, 100 and 98%, respectively) over each 
study individually (79) for the diagnosis of clinically significant CAD (63) in 
the per patient analysis. This is because CTCA may perform sub-optimally 
in the evaluation of stenosis severity, while PET may present challenges to 
discern between localized epicardial disease from microvascular affection. 
Furthermore, the information obtained can support or discourage 
unnecessary invasive angiographic assessments (80) and has demonstrated 
value in risk stratification and prognosis (81). Although a diagnostic 
approach in which CTCA is performed to exclude significant CAD to spare 
MPI has proven to be cost effective and to avoid an increase in utilization of 
other imaging methods (82), the increasingly evolving notion of benefit from 
complementary information from hybrid methods is evident as exemplified 
in Figure 9.
The advantages of such technical features of hybrid modalities 
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converge in the improved evaluation of subclinical and overt CAD and 
in the determination of early pathophysiological changes of the disease 
(intermediate risk) as well as complex disease in patients with long-standing 
CV disease features (multivessel disease with complex anatomy or chronic 
occlusions).
Recently PET/MR scanners offer attractive possibilities for combining 
measures of ventricular function, perfusion, viability, and infarct scar 
for evaluation of ischemic heart disease due to the intrinsic advantages 
of MR (no radiation exposure and higher spatial resolution). Then again, 
complementary value of PET/MR has to be demonstrated above the 
overlapping nature of the information provided. It has been stated that the 
greater contribution of PET/MR in the realm of cardiovascular disease will 
crystalize beyond CAD evaluation, for example, in the characterization of 
cardiomyopathies or infiltrative diseases (83,84).
In the clinical scenario, hybrid imaging should be justified according 
to the clinical question for the individual patients and the need for 
physiological data and precise anatomic delineation must be considered a 
feasible advantage of the equipment more than an automatic choice linked 
to the possibility of obtaining additional information (85).
CONCLUSION
PET myocardial perfusion currently represents the reference technique 
for quantitative perfusion assessment. The contribution of MBF and MPR 
to the traditional semi-quantitative evaluation of perfusion abnormalities 
improves diagnostic and prognostic performance in patients with CAD. 
Quantification of MBF with PET allows detection of early vasomotor 
abnormalities linked to subclinical disease, it permits treatment evaluation 
and it offers accurate diagnostic evaluation of patients with known or 
suspected atherosclerosis. Cardiac PET offers the possibility to evaluate left 
ventricular function in several of its components at no further expense and 
measures such as LVEF have provided added diagnostic value. Additionally, 
the prognostic performance of quantitative myocardial perfusion and 
function is steadily being recognized. New developments in available tracers 
and hybrid modalities will enhance the possibilities of accurate non-invasive 
imaging in several clinical scenarios.
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The clinical value of PET quantitative perfusion is expected to improve 
patient outcomes and optimize therapeutic decisions, which constitute key 
elements for the future of cardiovascular medicine. The consequences of 
the variety in methodologies are not yet fully examined and more insight 
into the interplay of the potentially obtainable measures with cardiac PET 
imaging is desirable.
AIM OF THE THESIS
The present thesis aims to deliver a contribution to our knowledge of 
methodological aspects of perfusion quantification as well as the partially 
characterized relationships between myocardial perfusion and ventricular 
function in the setting of several clinical conditions and varying levels of 
cardiovascular risk, with the utilization of the non-invasive state-of-the-art 
technology PET.
OUTLINE
The present thesis proceeds with Chapter 2, which will describe our 
exploration of the influence of quantitative myocardial perfusion and fixed 
perfusion defects (arising from an induced myocardial infarction) on left 
ventricular systolic function and the renal perfusion in a pre-clinical scenario 
using a rat model.
Chapter 3 advances into the investigation of the relative importance 
of absolute quantification parameters of myocardial perfusion (stress 
myocardial blood flow [MBF] and myocardial perfusion reserve [MPR]) in 
relation to complementary measurements of cardiac function, namely of: the 
systolic, diastolic and synchronic aspects. 
Next, Chapter 4 presents a study which focuses in a population of 
patients with history of a hard cardiovascular event (myocardial infarction) in 
order to evaluate the association of a novel evaluation of absolute myocardial 
perfusion (in the MI-spared myocardium) and the size of the infarcted area 
with the residual systolic function. 
The clinical section of the thesis will start with the “Intermedio” 
(Chapter 5). An interesting case of abnormal perfusion findings in which 
absolute quantification of myocardial perfusion and complementary CT 
The current state of  quantification of  myocardial perfusion with PET
37
1
imaging revealed the true extent and origin of the perfusion abnormalities 
will be presented.
Further, attention will be focused into particular aspects of other 
pathological determinants of cardiac function. In Chapter 6 a study in non-
infarcted type 2 diabetes mellitus patients, which addresses the independent 
influence of a highly relevant morbidity on cardiac function, will be delivered.
A statement is presented on the systematically-approached current 
evidence of the prognostic value of the absolute quantification (a unique 
characteristic of PET imaging, for which it represents the gold standard) in 
the occurrence of adverse (both fatal and non-fatal) cardiovascular events 
(Chapter 7). 
In the last section (Chapter 8), future perspectives in the area of non-
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